Connect with us


Mainz-based biotech company ActiTrexx receives €3.5 million in financing

The biotech company ActiTrexx has recently closed a Series A financing round, during which it raised $4.2 million (€3.5 million). In addition, ActiTrexx will receive funding from the GO-Bio program of the German Federal Ministry of Education and Research (BMBF) for the successful start of the company.



ActiTrexx GmbH, a young biotech spin-off of the University Medical Center Mainz, has closed its Series A financing. A consortium led by LBBW Venture Capital GmbH with participation of MediVentures GmbH, High-Tech Gründerfonds (HTGF) and Investitions- und Strukturbank Rheinland-Pfalz (ISB) invests a total of $4.2 million (€3.5 million).

If you want to read more about the biotech company ActiTrexx GmbH and to be the first to find the most important finance news of the day, download for free the Born2Invest mobile app. 

ActiTrexx: Prevention of exaggerated immune reactions

ActiTrexx is developing the product candidate ATreg, activated regulatory T cells (Tregs), which are stimulated by means of a proprietary process to prevent rejection reactions in transplant patients and excessive immune responses in autoimmune diseases. For this purpose, the regulatory T cells, as natural guardian cells of the immune system, are activated outside the body by a proprietary method and administered to patients as an infusion. The team led by Prof. Andrea Tüttenberg and Dr. Helmut Jonuleit from the Mainz Department of Dermatology intends to use the funds raised to further optimize and clinically test the novel cell therapy.

First clinical trials to take place this year

The first clinical trials for the treatment of leukemia patients after stem cell transplantation, in whom the risk of life-threatening transplant rejection, graft-versus-host disease (GvHD), is particularly high, are to start as early as 2021 in cooperation with the III Medical Clinic of the University Medical Center Mainz. Preclinical data have shown that ATreg can significantly attenuate pre-existing GvHD. Accordingly, a preventive treatment can largely prevent the development of the disease.

“If these observations can be confirmed in patients in the clinic, ATreg may be the cornerstone for a new, effective GvHD therapy with few side effects,” said Prof. Tüttenberg, CEO of ActiTrexx.

Manufacturing processes shortened to hours

In the past, regulatory T cells have been successfully used in academic studies for GvHD therapy. “However, the approach we are using represents a significant improvement over previously existing protocols due to the unique activation of Tregs. The ATreg product shortens the manufacturing process for Treg-based cell therapies from weeks to hours, and use of the cell preparation can thus take place within a very short time. This is of particular benefit to patients with acute GvHD who urgently need therapy,” added Dr. Jonuleit, CSO of ActiTrexx.

“The development of therapeutics to suppress an undesired immune response in stem cell and organ transplantation as well as autoimmune diseases is currently the focus of various biotech companies worldwide. However, the therapeutic application of regulatory T cells in this field has so far been limited by time-consuming and cost-intensive procedures,” explained Dr. Stefanie Wojciech, Investment Manager at LBBW VC. The therapy with ATreg is expected to undergo clinical testing already this year and should be available to the first patients in a few years.

In addition, ActiTrexx will receive funding from the GO-Bio program of the German Federal Ministry of Education and Research (BMBF) for the successful start of the company. The founders had already raised four million euros in funding in 2016 as part of the GO-Bio startup initiative. The company was founded only last year.


(Featured image by lapping via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.